Law Offices of Thomas J. Lamb

  • Free Case Evaluation
  • Mesothelioma & Asbestos Diseases
  • Legal Compensation
  • Asbestos Overview
  • Common Questions
  • About Our Firm

Immunotherapy Making Headway in SCLC and Mesothelioma

March 21, 2018 By Thomas Lamb

Immune-based therapies continue to show promising signals for patients with small cell lung cancer (SCLC) and mesothelioma, but better predictive biomarkers are needed to determine who is most likely to benefit, according to Justin F. Gainor, MD.

The rationale for immunotherapy in SCLC is growing because it is a very molecularly complex disease, Gainor said in a presentation during the 5th Annual Miami Lung Cancer Conference. While PD-L1 expression is infrequent in this space, SCLC tumors can be characterized by relatively high tumor mutation burden (TMB).

“We’ve seen responses with PD-1 monotherapy as well as with dual checkpoint blockade regardless of PD-L1 status,” said Gainor, assistant professor of medicine at Harvard Medical School and an assistant in medicine at Massachusetts General Hospital. “The combination of PD-1/CTLA-4 is associated with a higher response rate compared with nivolumab alone, but this benefit appears to be most pronounced in high TMB patients.”

Signals with checkpoint inhibitors were first reported with pembrolizumab (Keytruda) in the multi-cohort KEYNOTE-028 trial, which showed that the PD-1 inhibitor pembrolizumab was associated with a 33% overall response rate (ORR) in patients with PD-L1-positive SCLC. Of all patients enrolled on the study, 31.7% tested PD-L1 positive, defined as ?1% PD-L1 expression in tumor and inflammatory cells or stroma.

Nivolumab (Opdivo) has also been investigated in several SCLC studies. The open-label, phase I/II CheckMate-032 trial, for example, evaluated 216 patients with progressive SCLC who had received ?1 prior platinum-containing regimen and were not stratified for PD-L1 expression. Patients were randomly assigned to single-agent nivolumab or the combination of nivolumab and ipilimumab (Yervoy) at 1 of 2 doses.

[Article continues at original source]


 Mesothelioma, Asbestos, and Legal Compensation: Basic Facts

Asbestos-Mesothelioma Case Evaluation Form
Free.  Confidential.  No Obligation.

Filed Under: Medicine, Mesothelioma Tagged With: asbestos-related cancer, lung cancer, malignant mesothelioma, mesothelioma, mesothelioma treatments

Do I Have A Possible Case?

If you have a possible asbestos disease or mesothelioma lawsuit, you can get a free, confidential, and no obligation case review from asbestos lawyer Tom Lamb.

Main Navigation Menu

  • Who Was Exposed to Asbestos
  • NC Asbestos Exposure Sites
  • Asbestos-Contaminated Talc
  • Asbestos Diseases
  • Legal Compensation
  • Free Case Evaluation
  • Frequently Asked Questions
  • About Our Law Firm
  • Attorney Tom Lamb
  • Collection of Articles
  • Sitemap

Attorney Tom Lamb

TJL@LambLawOffice.com

Phone: 800-426-9535

Lumina Station, Suite 225
1908 Eastwood Road
Wilmington, North Carolina

Please know that you can use our Quick Contact Form to tell us about your case.

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Website

Lamb Law Office

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.